Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

44.07 +0.05 (+0.11%)
Streaming Delayed Price Updated: 12:27 PM EDT, Oct 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
27 28 29 30 31 32 33 34 Next >
FDA Advisory Committee Votes in Favor of Maintaining Accelerated Approval of Genentech’s Tecentriq for PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
From Genentech
Via Business Wire
Tuesday Market Report
Swiss ABB gained 0.8% more today after it reported on its Q1 today, confirming the pre-announced data from earlier in April. 
Via Talk Markets
Disruptor Alert: These 2 Companies Are Changing Cancer Care
Their liquid biopsies are giving doctors new and better tools to spot, track, and treat cancers. 
Via The Motley Fool
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:... 
Via Benzinga
Roche, AbbVie, Bristol-Myers Are Latest To Win European Medicines Agency's CHMP Positive Opinion
European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of Roche Holdings AG’s (... 
Via Benzinga
The Daily Biotech Pulse: Quidel Slides On Negative Pre-Announcement, Roche Gets Positive EMA Committee Recommendation, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 22) AtriCure, Inc. (NASDAQ:... 
Via Benzinga
Earth Day
Once again the exchanges are unsure if they want to go up or down. 
Via Talk Markets
Cathie Wood Loads Up Heavily On Debutant Uipath, Trims Tesla
Cathie Wood-led Ark Investment Management on Wednesday snapped up millions of shares of the New York-based software automation company UiPath Inc (NYSE: PATH) on the day that it... 
Via Benzinga
Gold Is Back
Wednesday was another mixed day with oil stocks and foreign telcos up from demand rising--but US telcos going their own ways, with AT&T up, and Verizon down because it lost wireless subs. 
Via Talk Markets
Roche Backs 2021 Outlook Despite Lackluster Q1 Performance In Pharmaceuticals Division
Roche Holdings AG (OCTMKTS: RHHBY) posted Q1 sales of CHF 14.9 billion, up 3% Y/Y on a constant currency basis and down 1% on a reported basis. Sales in the... 
Via Benzinga
The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 20) Alexion Pharmaceuticals,... 
Via Benzinga
Cathie Wood Loads Up On DraftKings, Coinbase, Palantir, Sells Nvidia, Square
Cathie Wood-led Ark Investment Management on Tuesday snapped up another 236,348 shares of cryptocurrency exchange Coinbase Global... 
Via Benzinga
Cathie Wood Buys Peloton, Coinbase Dips, Cuts Nvidia Stake
Cathie Wood-led Ark Investment Management on Monday snapped up shares of the exercise bike maker Peloton Interactive Inc (NASDAQ: 
Via Benzinga
Currency Manipulation
London's FTSE 100 index today rose over 7000 for the first time in 14 months. It hit 7019.53. 
Via Talk Markets
The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15) Ardelyx, Inc. (NASDAQ:... 
Via Benzinga
New Data for Genentech’s Ocrevus (ocrelizumab) Reinforce Significant Benefit on Slowing Disease Progression in Relapsing and Primary Progressive Multiple Sclerosis
From Genentech
Via Business Wire
The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 14) 10x Genomics, Inc. (NASDAQ... 
Via Benzinga
Genentech’s Evrysdi Continues to Improve Motor Function and Survival in Babies With Type 1 Spinal Muscular Atrophy (SMA)
From Genentech
Via Business Wire
Electric Cancer Cure
Most US stocks were down on fear of inflation and financial risks but then rose after lunch. 
Via Talk Markets
FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
From Genentech
Via Business Wire
The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 12) 180 Life Sciences Corp. (... 
Via Benzinga
Cardiff Oncology's Onvansertib Shows Durable Response, Progression-Free Survival In Colorectal Cancer Patients
Cardiff Oncology Inc (NASDAQ: CRDF) has announced data from its ongoing Phase 1b/2 trial evaluating onvansertib combined with standard-of-care therapy in... 
Via Benzinga
New Genentech Data at 2021 AAN Highlight Impact and Breadth of Expanding Neuroscience Portfolio
From Genentech
Via Business Wire
The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 6) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
Topics Intellectual Property
< Previous 1 2
...
27 28 29 30 31 32 33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.